Gracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients

  • Gracell Biotechnologies Inc GRCL announced the updated clinical data on GC012F, an autologous CAR-T therapeutic candidate dual-targeting B-cell maturation antigen (BCMA) and CD19, for relapsed/refractory multiple myeloma (RRMM).
  • From October 2019 to January 2022, 29 heavily pretreated patients were enrolled and treated with a single infusion of GC012F at three dose levels (DL).
  • At the data cutoff of June 8, 2022, the response rate at different dose levels was 100% (2/2) in DL1, 80% (8/10) in DL2, and 100% (17/17) in DL3. 
  • All 29 patients achieved minimal residual disease (MRD) negativity. 75.9% of all patients treated achieved MRD-sCR. At the data cutoff, the median duration of response (DOR) was 15.7 months.
  • The safety profile of GC012F was consistent with previous findings with a primarily low grade of cytokine release syndrome (CRS).
  • Additionally, Gracell presented the first results of Phase 1 investigator-initiated study in China of GC012F in B-cell non-Hodgkin's lymphoma patients.
  • All three patients achieved a complete response (CR) confirmed at day 28 after GC012F infusion. 
  • At the 3-month follow-up, both assessable patients had an ongoing response. No dose-limiting toxicities and immune effector cell-associated neurotoxicity syndrome were observed. 
  • CRS presented as Grade 1 in two patients and Grade 3 in one patient with no Grade 4 or 5 events.
  • Price Action: GRCL shares are down 13.11% at $2.86 on the last check Monday.

Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving